Caribou Biosciences (CRBU) Projected to Post Earnings on Tuesday

Key Points

• Caribou Biosciences (CRBU) is set to release its Q2 2025 earnings results on August 5th, with analysts predicting an earnings per share of ($0.40) for the quarter.
• The company's previous earnings report showed a loss of ($0.43) per share but exceeded revenue expectations with $2.35 million compared to estimated $1.48 million.
• AQR Capital Management recently increased its stake in Caribou Biosciences by 741.6%, owning approximately 77.51% of the company's stock collectively among institutional investors.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) is expected to post its Q2 2025 quarterly earnings results before the market opens on Tuesday, August 5th. Analysts expect Caribou Biosciences to post earnings of ($0.40) per share for the quarter.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.43) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.43). Caribou Biosciences had a negative return on equity of 55.70% and a negative net margin of 1,490.84%. The business had revenue of $2.35 million during the quarter, compared to analysts' expectations of $1.48 million. On average, analysts expect Caribou Biosciences to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Caribou Biosciences Stock Performance

Shares of NASDAQ CRBU traded down $0.08 during trading on Friday, reaching $1.95. The stock had a trading volume of 1,248,372 shares, compared to its average volume of 1,940,261. Caribou Biosciences has a fifty-two week low of $0.66 and a fifty-two week high of $3.00. The business's 50-day moving average price is $1.51 and its 200-day moving average price is $1.22. The company has a market cap of $181.35 million, a P/E ratio of -1.20 and a beta of 2.55.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on CRBU shares. Wall Street Zen raised Caribou Biosciences from a "sell" rating to a "hold" rating in a research note on Saturday, July 5th. HC Wainwright reaffirmed a "buy" rating and issued a $3.00 price objective (down from $9.00) on shares of Caribou Biosciences in a research note on Monday, April 28th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $8.50.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Caribou Biosciences stock. AQR Capital Management LLC lifted its stake in Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) by 741.6% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 525,878 shares of the company's stock after purchasing an additional 463,391 shares during the period. AQR Capital Management LLC owned about 0.57% of Caribou Biosciences worth $480,000 at the end of the most recent quarter. 77.51% of the stock is owned by institutional investors and hedge funds.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.